Antibiotic-induced lymphoma remission in MALT lymphomas
| Involved organ . | Targeted pathogen . | Antibiotic regimen . | No. of patients . | Type of study . | Overall lymphoma remission rate, % . |
|---|---|---|---|---|---|
| Stomach | H pylori | Mostly PPI plus clarithromycin-based triple therapy with either amoxicillin or metronidazole for 10-14 d | 1408 | 32 studies either retrospective or prospective | 77.5 |
| Ocular adnexa | C psittaci | Doxycycline 100 mg | 120 | 2 prospective, | 48 |
| Twice daily ×21 d | 4 retrospective, 1 case report | ||||
| Clarithromycin* 500 mg | 11 | Prospective | 45 | ||
| Twice daily ×6 mo | |||||
| Clarithromycin* 2 g/d, days 1-14, every 21 d (4 courses) | 23 | Prospective | 52 | ||
| Skin | B burgdorferi | Ceftriaxone 2 g/d ×14 d (in most cases) | 5 | Case reports | 40 |
| Involved organ . | Targeted pathogen . | Antibiotic regimen . | No. of patients . | Type of study . | Overall lymphoma remission rate, % . |
|---|---|---|---|---|---|
| Stomach | H pylori | Mostly PPI plus clarithromycin-based triple therapy with either amoxicillin or metronidazole for 10-14 d | 1408 | 32 studies either retrospective or prospective | 77.5 |
| Ocular adnexa | C psittaci | Doxycycline 100 mg | 120 | 2 prospective, | 48 |
| Twice daily ×21 d | 4 retrospective, 1 case report | ||||
| Clarithromycin* 500 mg | 11 | Prospective | 45 | ||
| Twice daily ×6 mo | |||||
| Clarithromycin* 2 g/d, days 1-14, every 21 d (4 courses) | 23 | Prospective | 52 | ||
| Skin | B burgdorferi | Ceftriaxone 2 g/d ×14 d (in most cases) | 5 | Case reports | 40 |
The clarithromycin activity may also depend on the immunomodulatory and direct antitumor effect of this macrolide antibiotic.71